Tekgündüz E.Altuntaş F.Şivgin S.Aki Ş.Z.Dönmez A.Topçuoglu P.Yildirim R.Baysal N.A.Ayyildiz E.Yüksel M.K.Sari T.Tombuloglu M.Ünal A.Ilhan O.2019-10-262019-10-2620121473-0502https://doi.org/10.1016/j.transci.2012.05.004https://hdl.handle.net/11454/18537Plerixafor in conjunction with G-CSF (G-P) is an effective strategy for hematopoietic stem cell mobilization in patients with previously failed mobilization attempt. Here we report our results with G-P among patients with at least one mobilization failure with G-CSF alone (G) or G-CSF plus chemotherapy (G-C). The study included 20 consecutive patients with lymphoma and myeloma from five centers. In 14 (70%) patients, a minimum of 2×10 6/kg CD34+ stem cells were collected and 16 out of 20 patients (80%) were able to proceed to ASCT. Our study indicates that plerixafor can safely rescue patients with a history of mobilization failure. © 2012 Elsevier Ltd.en10.1016/j.transci.2012.05.004info:eu-repo/semantics/closedAccessChemotherapyMobilization failurePlerixaforStem cell mobilizationArticle471778022609192Q3